This year we will visit Medica. Medica is the world’s largest event for the medical sector. We will be in hall 3, 3a and 18. We are looking for new innovative products to distribute in the BeNeLux. ViennaLab will have their own booth on Medica this year.
realfast PCR assays on mutations and genetic disorders like Thalassemia, Cystic Fibrosis,The new RealFast assays this year on Pharmacogenetics are the IL28B and the SLC01B1 . On CVD RealFast assays the Factor XII, the Factor XIII and the FBG were released this year. The CF StripAssay® 38+1 is the new addition to the CF StripAssays®.
The IL28B RealFast™ Assay detects the TT>deltaG dinucleotide frame-shift variant in the human interferon lambda 4 (IFNL4) gene/pseudogene, which is located upstream of the gene encoding interleukin 28B (IL28B). Genoptying helps to predict the therapeutic response in Hepatitis C Virus (HCV) infected patients, who are being considered for pegylated-interferon/ribavirin (pegIFN/RBV) therapy. Homozygous carriers of the favorable TT allele are predisposed to an up to threefold higher sustained virological response (SVR) than carriers of the deltaG allele.
The SLCO1B1 c.521T>C RealFast™ Assay identifies the c.521T>C variant in the human solute carrier organic anion transporter familiy member 1B1 (SLCO1B1) gene. The c.521T>C variant, which is contained in the SLCO1B1*5, *15 and *17 alleles, leads to impaired function of the encoded transporter protein, and consequently to decreased hepatic uptake and increased plasma concentration of various drugs like statins. The kit is used to identify patients who are at higher risk for developing statin-induced myopathy.
The FGB -455G>A RealFast™ Assay is used to analyze the G>A transition at nucleotide position -455 in the promoter region of the human Fibrinogen beta-chain (FGB) gene. The mutation is associated with an elevated plasma fibrinogen level, which is considered to be an independent risk factor for vascular disease. The kit is designed to identify homozygous at-risk patients who may have increased susceptibility to atherothrombotic complications. The FGB -455G>A polymorphism is also part of the ViennaLab CVD StripAssay A.
The FXII 46C>T RealFast™ Assay detects the 46C>T mutation in the human coagulation Factor XII (F12) gene. Homozygosity for the T allele has been reported to be a risk factor for venous thrombosis in several studies. The kit is designed to identify patients with the unfavorable TT genotype, who may have an increased susceptibility to thrombotic disorders.
The FXIII V34L RealFast™ Assay identifies a G>T transition in exon 2 of the human coagulation Factor XIII (F13A) gene. This polymorphism leads to a valine (V) to leucine (L) substitution at amino acid 34 of the FXIII subunit A. The L variant has been described as having a small but significant protective effect against both arterial and venous thrombosis. The kit is designed to identify carriers of the 34L variant among at-risk patients of hereditary thrombophilia. The FXIII V34L polymorphism is also part of the ViennaLab CVD StripAssay T.